Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) and Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) are both small-cap medical companies, but which is the superior investment? ProfitabilityNet Margins Return on Equity Return on Assets Phathom Pharmaceuticals -289.51% N/A -90.40% Allogene Therapeutics N/A -55.99% -42.75%Earnings and ValuationThis table compares Phathom Pharmaceuticals and Allogene Therapeutics’ net margins, return on equity and return on assets. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phathom Pharmaceuticals $55.25 million 15.68 -$334.33 million ($4.73) -2.58 Allogene Therapeutics $20,000.00 14,755.02 -$257.59 million ($1.11) -1.20Allogene Therapeutics has lower revenue, but higher earnings than Phathom Pharmaceuticals. Analyst RecommendationsThis is a summary of recent recommendations and price targets for Phathom Pharmaceuticals and Allogene Therapeutics, as reported by MarketBeat.com. Given Allogene Therapeutics’ higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than Phathom Pharmaceuticals.